Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix Biotherapeutics, focusing on the discovery and development of conditional polyspecific antibodies for oncology and inflammatory diseases. The collaboration underscores Gilead’s commitment to advancing innovative treatments in these therapeutic areas.
Financial Terms and Acquisition Rights
Under the terms of the agreement, Tentarix will receive an upfront payment of USD 66 million and an equity investment from Gilead. Additionally, Gilead will secure the rights to acquire up to three Tentarix subsidiaries that own the resulting products for USD 80 million each. This strategic investment positions Gilead to potentially expand its portfolio with new therapeutic options for patients.
Leveraging Tentarix’s Proprietary Platform
The project will capitalize on Tentarix’s proprietary platform, which identifies receptor combinations on immune cells to ensure the specificity of the polyspecific antibodies. These antibodies are designed to recruit immune cells, preventing the activation of other pathways towards off-target sites. This precision approach aims to enhance the efficacy and safety of treatments for oncology and inflammatory diseases.-Fineline Info & Tech
